Evolent Health, Inc. (NYSE:EVH) Given Consensus Rating of “Buy” by Brokerages

Shares of Evolent Health, Inc. (NYSE:EVH) have received an average recommendation of “Buy” from the twelve research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $26.18.

Several research firms have weighed in on EVH. Barclays decreased their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Stephens lowered Evolent Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $38.00 to $16.00 in a research report on Friday, November 8th. JPMorgan Chase & Co. cut their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, November 22nd. BTIG Research decreased their price objective on Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, December 3rd. Finally, Citigroup cut their target price on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Hedge Funds Weigh In On Evolent Health

Several large investors have recently bought and sold shares of EVH. Wellington Management Group LLP grew its stake in shares of Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock worth $356,200,000 after acquiring an additional 1,426,747 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Evolent Health by 1,948.5% during the third quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after purchasing an additional 1,422,385 shares during the last quarter. William Blair Investment Management LLC grew its position in Evolent Health by 35.2% in the 2nd quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after purchasing an additional 1,308,376 shares in the last quarter. First Light Asset Management LLC increased its stake in Evolent Health by 401.5% in the 2nd quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company’s stock valued at $27,634,000 after buying an additional 1,157,124 shares during the last quarter. Finally, Bellevue Group AG lifted its position in shares of Evolent Health by 59.9% during the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock worth $75,509,000 after buying an additional 1,000,215 shares in the last quarter.

Evolent Health Stock Performance

NYSE:EVH opened at $11.27 on Thursday. The firm has a market capitalization of $1.31 billion, a P/E ratio of -12.38 and a beta of 1.45. Evolent Health has a twelve month low of $10.53 and a twelve month high of $35.00. The company has a fifty day moving average of $15.73 and a 200-day moving average of $21.91. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.